Cullen/Frost Bankers Inc. reports strong quarterly earnings, driven by disciplined credit management and strategic expansion, while outlining a cautious yet opportunistic outlook for 2026 in a shifting rate environment.
Robinhood Markets is making a bold two-pronged move, expanding its tokenized stock offerings while positioning itself as a key retail gateway for SpaceX's anticipated IPO. This strategy underscores its ambition to democratize high-profile investments but also intensifies scrutiny on its regulatory risks and valuation.
Shares of gaming and hospitality REIT VICI Properties have faced recent headwinds, trading near $28 and presenting a significant discount to analyst targets. We examine whether the current valuation gap signals a buying opportunity or reflects deeper sectoral risks.
A recent analyst price target update for Tesla, devoid of specific figures, has reignited debate over the core drivers of the stock's story. The focus is shifting from pure growth metrics to the underlying expectations and perceived risks surrounding its business model and long-term strategy.
Exxon Mobil's fourth-quarter results surpassed expectations, driven by record production in the Permian Basin and Guyana alongside significant cost savings. While the strong performance has propelled the stock higher, analysts are divided on whether its current valuation fully prices in future growth or exposes investors to downside risk.
The British government's move to retroactively alter leasehold ground rent contracts is undermining a foundational pillar of its investment landscape: trust in the rule of law. This erosion of contractual certainty risks deterring the long-term capital essential for growth, from energy to AI infrastructure.
Australian miner ioneer has secured A$72 million in fresh capital to advance its flagship Nevada lithium-boron project. While the funds de-risk near-term construction, the discounted share placement sparks debate over strategic leverage versus shareholder dilution in a critical minerals race increasingly shaped by U.S. industrial policy.
A new report from crypto market maker Wintermute Ventures forecasts a seismic shift, arguing that blockchain-based prediction markets will begin displacing traditional insurance by making hyper-specific risks tradable. The firm outlines a future where decentralized infrastructure becomes the new clearing layer for a programmable global economy.
A volatile January has underscored a stark shift for investors: political shocks emanating from Washington now pose a greater threat to portfolios than traditional economic or earnings concerns, reshaping risk calculus across global markets.
Amid ongoing market volatility, financial professionals are urging middle-income households to steer clear of cryptocurrency investments, citing a toxic mix of extreme risk, lack of regulation, and the potential to derail long-term financial security.
As the 2027 deadline for Swift's Case Management standard approaches, banks face a strategic inflection point. Early adopters of native processing are poised to unlock operational resilience and revenue growth, while laggards risk entrenched inefficiency and competitive decline.
After years of share price weakness, Immunocore Holdings (IMCR) appears significantly undervalued by traditional metrics. But does the market know something the models don't? We examine the DCF and P/S analyses, the company's unique T-cell receptor platform, and the risks that have kept investors wary.
Specialty insurer Kinsale Capital Group continues to outpace broader industry growth in key metrics, driven by its focus on underserved, higher-risk markets. However, its premium valuation and recent stock volatility have intensified debate among investors about its long-term sustainability.
Following the FDA's decision to remove the clinical hold on Intellia's Nex-Z hATTR-PN trial, analysts at Baird and H.C. Wainwright have significantly raised their price targets for the CRISPR gene-editing pioneer, citing reduced regulatory risk and a clearer path forward.
Goldman Sachs has downgraded MoonLake Immunotherapeutics (MLTX) to Sell, highlighting the failed VELA-2 trial endpoint and persistent approval risks for its key drug, sonelokimab, despite a competing firm's more bullish outlook.
Digital asset investment products witnessed their largest weekly capital flight since late 2025, with Bitcoin and Ethereum bearing the brunt of a $1.73 billion exodus. The sell-off, concentrated in the U.S., underscores a sharp pivot in risk appetite amid shifting macroeconomic winds, though Solana and select regions bucked the trend with modest inflows.
Twist Bioscience kicks off fiscal 2026 with robust growth, reporting a 17% year-over-year revenue increase to $103.7 million. The company credits its semiconductor-based DNA synthesis platform and surging demand from AI-enabled drug discovery programs as key drivers, while reiterating its path to adjusted EBITDA breakeven within the year.
Investment firm Curreen Capital posted strong 2025 results, crediting its focus on undervalued 'ugly duckling' stocks. The fund's latest letter spotlights VF Corporation (VFC), the embattled owner of Vans and The North Face, as a potential turnaround play despite its shares falling over 20% in the past year.
Investment firm Curreen Capital posted a 30.97% annual return for 2025, crediting its focus on undervalued, well-managed companies. The firm's latest investor letter highlights home service provider Frontdoor (FTDR) as a key holding, despite it not being among the most popular hedge fund picks.
After a prolonged correction, Brent crude oil is showing signs of a potential trend reversal, with a forming double bottom pattern pointing toward a technical target near $95 per barrel. The shift comes amid a tightening physical market and simmering geopolitical risks.
